Astellas and Pantherna enter into a new research technology evaluation agreement with Expanded Target Organ for the generation of mRNA-based regenerative medicine programs using direct reprogramming.

Tokyo and Hennigsdorf, GermanyAnd the October 3, 2022 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji YasukawaPh.D., “Astellas”) and Pantherna Therapeutics GmbH (CEO: Klaus Giese, Ph.D., “Pantherna”) today announced that the companies have entered into a new technology evaluation agreement for research to generate regenerative mRNA-based medicine programs using direct reprogramming (transformation) *.

This agreement expands the scope of the Technology Assessment Agreement for Research, which Astellas and Pantherna come into operation in 2021to include the new target device.

Pantherna has a proprietary platform of the latest unique mRNA molecules (PTXmRNAs) to enhance the efficiency of mRNA actions in the body. Under the new agreement, Pantherna’s mRNA platform will be combined with Astellas’ global drug discovery capabilities to advance research on the generation of regenerative medicine programs for new target organs using a direct reprogramming approach. Astellas will be responsible for providing drug discovery ideas, preparing candidate compounds for technology evaluation, and conducting research aimed at developing this therapeutic method, while Pantherna will be responsible for providing technical information and development support.

“We are excited about this expansion of our collaboration with Astellas,” Pantherna CEO said, Klaus Geese, Ph.D. “We are proud that Astellas, as a leading pharmaceutical company, has confirmed its interest in leveraging the unique aspects of our therapeutic mRNA technology.”

“Through this agreement, which expands our collaboration with Pantherna, we will establish innovative regenerative medicine programs for new target organs, and we expect to be able to expand treatment options for diseases with high unmet medical needs.” He said Taiji Sawamoto, Ph.D., Executive Vice President, Applied Research and Operations, Astellas. “The collaboration with Pantherna is an initiative that synergistically integrates Astellas’ expertise with mRNA as a therapeutic modality and its research-implanted capabilities for direct reprogramming, and will promote the development of next-generation therapies using a new method/technology based on the focus area approach strategy.”

* Direct reprogramming: direct conversion of cell fate without going through the pluripotent state.

About Astellas
Astellas Pharma Inc. It is a pharmaceutical company that does business in more than 70 countries around the world. We promote a focus area approach designed to identify opportunities for continuous innovation of new drugs to treat diseases with high unmet medical needs by focusing on biology and method. Furthermore, we are also looking beyond our primary focus on Rx to create Rx+® Healthcare solutions that combine our experience and knowledge with the latest technologies in various fields of external partners. Through these efforts, Astellas is at the forefront of change in healthcare to turn innovative science into value for patients. For more information, please visit our website at

About Pantherna
Pantherna Therapeutics is a privately owned biopharmaceutical company that develops first-class treatments for vascular diseases. Pantherna’s innovative technology platform relies on advanced lipid nanoparticles for selective delivery and expression of therapeutic mRNA drugs in organs and tissues such as the endothelium. Pantherna Therapeutics was recently awarded the 2022 Pharma Trend Honor for its lead candidate PAN004 in the “Most Innovative Product: Leap Innovations-Nucleic Acid-Based Drug Development” category.

( Pharmaceutical-Companies-and-the-Most-Innovative-Products_2022). Pantherna is headquartered in Hennigsdorf, Brandenburg (Innovationsforum) near Berlin Germany. For more information, please visit our website at

Cautionary Notes (Astellas)
In this press release, statements made regarding current plans, estimates, strategies, beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. These factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations relating to drug markets, (ii) currency exchange rate fluctuations, (iii) delays in launching a new product, (iv) the inability of Astellas to market Effectively existing and new products, (5) the inability of Astellas to continue to effectively research and develop products acceptable to customers in highly competitive markets, and (6) infringements of Astellas intellectual property rights by third parties.

The information regarding pharmaceutical products (including products currently in development) included in this press release is not intended to constitute advertising or medical advice.

Source: Astellas Pharma Inc.

Leave a Comment